Promiscuous glycan site recognition by antibodies to the high-mannose patch of gp120 broadens neutralization of HIV

Science Translational Medicine

Volumn 6, Issue 236, 2014, Pages

  Sok, Devin ^a   Doores, Katie J ^a,b   Briney, Bryan ^a   Le, Khoa M ^a   Saye Francisco, Karen L ^a   Ramos, Alejandra ^a,c   Kulp, Daniel W ^a,c   Julien, Jean Philippe ^a   Menis, Sergey ^a,c   Wickramasinghe, Lalinda ^a,c   Seaman, Michael S ^d   Schief, William R ^a,c,e   Wilson, Ian A ^a   Poignard, Pascal ^a,c   Burton, Dennis R ^a,e  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b GUY S HOSPITAL   (United Kingdom)

^c INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BROADLY NEUTRALIZING MONOCLONAL ANTIBODY; EPITOPE; GLYCAN; GLYCOPROTEIN GP 120; MANNOSE; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; IMMUNOGLOBULIN G; POLYSACCHARIDE;

ANTIGEN BINDING; ANTIGEN RECOGNITION; ARTICLE; CONTROLLED STUDY; HUMAN IMMUNODEFICIENCY VIRUS; MOLECULAR MODEL; NONHUMAN; PRIORITY JOURNAL; VIRUS ENVELOPE; VIRUS NEUTRALIZATION; BINDING SITE; CHEMISTRY; ENZYME LINKED IMMUNOSORBENT ASSAY; GLYCOSYLATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC50; IMMUNOLOGY; MOLECULAR GENETICS; SERODIAGNOSIS; TIME;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; BINDING SITES; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; GLYCOSYLATION; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV SEROPOSITIVITY; HIV-1; HUMANS; IMMUNOGLOBULIN G; INHIBITORY CONCENTRATION 50; MANNOSE; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; POLYSACCHARIDES; TIME FACTORS;

EID: 84901236516     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3008104     Document Type: Article

References (44)

1. D. R. Burton, R. Ahmed, D. H. Barouch, S. T. Butera, S. Crotty, A. Godzik, D. E. Kaufmann, M. J. McElrath, M. C. Nussenzweig, B. Pulendran, C. N. Scanlan, W. R. Schief, G. Silvestri, H. Streeck, B. D. Walker, L. M. Walker, A. B. Ward, I. A. Wilson, R. Wyatt, A blueprint for HIV vaccine discovery. Cell Host Microbe 12, 396-407 (2012).
2. L. Stamatatos, L. Morris, D. R. Burton, J. R. Mascola, Neutralizing antibodies generated during natural HIV-1 infection: Good news for an HIV-1 vaccine? Nat. Med. 15, 866-870 (2009).
3. J. R. Mascola, D. C. Montefiori, The role of antibodies in HIV vaccines. Annu. Rev. Immunol. 28, 413-444 (2010).
4. F. Klein, A. Halper-Stromberg, J. A. Horwitz, H. Gruell, J. F. Scheid, S. Bournazos, H. Mouquet, L. A. Spatz, R. Diskin, A. Abadir, T. Zang, M. Dorner, E. Billerbeck, R. N. Labitt, C. Gaebler, P. M. Marcovecchio, R. B. Incesu, T. R. Eisenreich, P. D. Bieniasz, M. S. Seaman, P. J. Bjorkman, J. V. Ravetch, A. Ploss, M. C. Nussenzweig, HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature 492, 118-122 (2012).
5. D. H. Barouch, J. B. Whitney, B. Moldt, F. Klein, T. Y. Oliveira, J. Liu, K. E. Stephenson, H. W. Chang, K. Shekhar, S. Gupta, J. P. Nkolola, M. S. Seaman, K. M. Smith, E. N. Borducchi, C. Cabral, J. Y. Smith, S. Blackmore, S. Sanisetty, J. R. Perry, M. Beck, M. G. Lewis, W. Rinaldi, A. K. Chakraborty, P. Poignard, M. C. Nussenzweig, D. R. Burton, Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature 503, 224-228 (2013).
6. M. Shingai, Y. Nishimura, F. Klein, H. Mouquet, O. K. Donau, R. Plishka, A. Buckler-White, M. Seaman, M. Piatak, J. D. Lifson, D. S. Dimitrov, M. C. Nussenzweig, M. A. Martin, Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature 503, 277-280 (2013).
7. J. Huang, G. Ofek, L. Laub, M. K. Louder, N. A. Doria-Rose, N. S. Longo, H. Imamichi, R. T. Bailer, B. Chakrabarti, S. K. Sharma, S. M. Alam, T. Wang, Y. Yang, B. Zhang, S. A. Migueles, R. Wyatt, B. F. Haynes, P. D. Kwong, J. R. Mascola, M. Connors, Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 491, 406-412 (2012).
8. L. M. Walker, M. Huber, K. J. Doores, E. Falkowska, R. Pejchal, J. P. Julien, S. K. Wang, A. Ramos, P. Y. Chan-Hui, M. Moyle, J. L. Mitcham, P. W. Hammond, O. A. Olsen, P. Phung, S. Fling, C. H. Wong, S. Phogat, T. Wrin, M. D. Simek, P. G. P. Investigators, W. C. Koff, I. A. Wilson, D. R. Burton, P. Poignard, Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477, 466-470 (2011).
9. L. M. Walker, S. K. Phogat, P.-Y. Chan-Hui, D. Wagner, P. Phung, J. L. Goss, T. Wrin, M. D. Simek, S. Fling, J. L. Mitcham, J. K. Lehrman, F. H. Priddy, O. A. Olsen, S. M. Frey, P. W. Hammond; Protocol G Principal Investigators, S. Kaminsky, T. Zamb, M. Moyle, W. C. Koff, P. Poignard, D. R. Burton, Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326, 285-289 (2009).
10. X. Wu, Z. Y. Yang, Y. Li, C. M. Hogerkorp, W. R. Schief, M. S. Seaman, T. Zhou, S. D. Schmidt, L. Wu, L. Xu, N. S. Longo, K. McKee, S. O'Dell, M. K. Louder, D. L. Wycuff, Y. Feng, M. Nason, N. Doria-Rose, M. Connors, P. D. Kwong, M. Roederer, R. T. Wyatt, G. J. Nabel, J. R. Mascola, Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329, 856-861 (2010).
11. H. X. Liao, R. Lynch, T. Zhou, F. Gao, S. M. Alam, S. D. Boyd, A. Z. Fire, K. M. Roskin, C. A. Schramm, Z. Zhang, J. Zhu, L. Shapiro; NISC Comparative Sequencing Program, J. Becker, B. Benjamin, R. Blakesley, G. Bouffard, S. Brooks, H. Coleman, M. Dekhtyar, M. Gregory, X. Guan, J. Gupta, J. Han, A. Hargrove, S. L. Ho, T. Johnson, R. Legaspi, S. Lovett, Q. Maduro, C. Masiello, B. Maskeri, J. McDowell, C. Montemayor, J. Mullikin, M. Park, N. Riebow, K. Schandler, B. Schmidt, C. Sison, M. Stantripop, J. Thomas, P. Thomas, M. Vemulapalli, A. Young, J. C. Mullikin, S. Gnanakaran, P. Hraber, K. Wiehe, G. Kelsoe, G. Yang, S. M. Xia, D. C. Montefiori, R. Parks, K. E. Lloyd, R. M. Scearce, K. A. Soderberg, M. Cohen, G. Kamanga, M. K. Louder, L. M. Tran, Y. Chen, F. Cai, S. Chen, S. Moquin, X. Du, M. G. Joyce, S. Srivatsan, B. Zhang, A. Zheng, G. M. Shaw, B. H. Hahn, T. B. Kepler, B. T. M. Korber, P. D. Kwong, J. R. Mascola, B. F. Haynes, Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature 496, 469-476 (2013).
12. J. F. Scheid, H. Mouquet, B. Ueberheide, R.Diskin, F. Klein, T. Y. K. Oliveira, J. Pietzsch, D. Fenyo, A. Abadir, K. Velinzon, A. Hurley, S. Myung, F. Boulad, P. Poignard, D. R. Burton, F. Pereyra, D. D. Ho, B. D. Walker, M. S. Seaman, P. J. Bjorkman, B. T. Chait, M. C. Nussenzweig, Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 333, 1633-1637 (2011).
13. P. D. Kwong, J. R. Mascola, Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. Immunity 37, 412-425 (2012).
14. D. Corti, A. Lanzavecchia, Broadly neutralizing antiviral antibodies. Annu. Rev. Immunol. 31, 705-742 (2013).
15. R. Pejchal, K. J. Doores, L. M. Walker, R. Khayat, P. S. Huang, S. K. Wang, R. L. Stanfield, J. P. Julien, A. Ramos, M. Crispin, R. Depetris, U. Katpally, A. Marozsan, A. Cupo, S. Maloveste, Y. Liu, R. McBride, Y. Ito, R. W. Sanders, C. Ogohara, J. C. Paulson, T. Feizi, C. N. Scanlan, C. H. Wong, J. P. Moore, W. C. Olson, A. B. Ward, P. Poignard, W. R. Schief, D. R. Burton, I. A. Wilson, A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science 334, 1097-1103 (2011).
16. L. Kong, J. H. Lee, K. J. Doores, C. D. Murin, J. P. Julien, R. McBride, Y. Liu, A. Marozsan, A. Cupo, P. J. Klasse, S. Hoffenberg, M. Caulfield, C. R. King, Y. Hua, K. M. Le, R. Khayat, M. C. Deller, T. Clayton, H. Tien, T. Feizi, R.W. Sanders, J. C. Paulson, J. P. Moore, R. L. Stanfield, D. R. Burton, A. B. Ward, I. A. Wilson, Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120. Nat. Struct. Mol. Biol. 20, 796-803 (2013).
17. J. P. Julien, D. Sok, R. Khayat, J. H. Lee, K. J. Doores, L. M. Walker, A. Ramos, D. C. Diwanji, R. Pejchal, A. Cupo, U. Katpally, R. S. Depetris, R. L. Stanfield, R. McBride, A. J. Marozsan, J. C. Paulson, R. W. Sanders, J. P. Moore, D. R. Burton, P. Poignard, A. B. Ward, I. A. Wilson, Broadly neutralizing antibody PGT121 allosterically modulates CD4 binding via recognition of the HIV-1 gp120 V3 base and multiple surrounding glycans. PLOS Pathog. 9, e1003342 (2013).
18. C. Bonomelli, K. J. Doores, D. C. Dunlop, V. Thaney, R. A. Dwek, D. R. Burton, M. Crispin, C. N. Scanlan, The glycan shield of HIV is predominantly oligomannose independently of production system or viral clade. PLOS One 6, e23521 (2011).
19. K. J. Doores, C. Bonomelli, D. J. Harvey, S. Vasiljevic, R. A. Dwek, D. R. Burton, M. Crispin, C. N. Scanlan, Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens. Proc. Natl. Acad. Sci. U.S.A. 107, 13800-13805 (2010).
20. E. P. Go, J. Irungu, Y. Zhang, D. S. Dalpathado, H. X. Liao, L. L. Sutherland, S. M. Alam, B. F. Haynes, H. Desaire, Glycosylation site-specific analysis of HIV envelope proteins (JR-FL and CON-S) reveals major differences in glycosylation site occupancy, glycoform profiles, and antigenic epitopes' accessibility. J. Proteome Res. 7, 1660-1674 (2008).
21. R. Pantophlet, D. R. Burton, GP120: Target for neutralizing HIV-1 antibodies. Annu. Rev. Immunol. 24, 739-769 (2006).
22. H.Mouquet, L. Scharf, Z. Euler, Y. Liu, C. Eden, J. F. Scheid, A. Halper-Stromberg, P. N. P. Gnanapragasam, D. I. R. Spencer, M. S. Seaman, H. Schuitemaker, T. Feizi, M. C. Nussenzweig, P. J. Bjorkman, Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies. Proc. Natl. Acad. Sci. U.S.A. 109, E3268-E3277 (2012).
23. J. M. Binley, T. Wrin, B. Korber, M. B. Zwick, M. Wang, C. Chappey, G. Stiegler, R. Kunert, S. Zolla-Pazner, H. Katinger, C. J. Petropoulos, D. R. Burton, Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J. Virol. 78, 13232-13252 (2004).
24. D. A. Calarese, C. N. Scanlan, M. B. Zwick, S. Deechongkit, Y. Mimura, R. Kunert, P. Zhu, M. R.Wormald, R. L. Stanfield, K. H. Roux, J.W. Kelly, P. M. Rudd, R. A. Dwek, H. Katinger, D. R. Burton, I. A. Wilson, Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science 300, 2065-2071 (2003).
25. C. N. Scanlan, R. Pantophlet, M. R. Wormald, E. Ollmann Saphire, R. Stanfield, I. A.Wilson, H. Katinger, R. A. Dwek, P. M. Rudd, D. R. Burton, The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of α1→2 mannose residues on the outer face of gp120. J. Virol. 76, 7306-7321 (2002).
26. R. W. Sanders, M. Venturi, L. Schiffner, R. Kalyanaraman, H. Katinger, K. O. Lloyd, P. D. Kwong, J. P. Moore, The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J. Virol. 76, 7293-7305 (2002).
27. B. Moldt, E. G. Rakasz, N. Schultz, P. Y. Chan-Hui, K. Swiderek, K. L. Weisgrau, S. M. Piaskowski, Z. Bergman, D. I. Watkins, P. Poignard, D. R. Burton, Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. Proc. Natl. Acad. Sci. U.S.A. 109, 18921-18925 (2012).
28. E. S. Gray, M. C. Madiga, T. Hermanus, P. L. Moore, C. K. Wibmer, N. L. Tumba, L. Werner, K.Mlisana, S. Sibeko, C. Williamson, S. S. Abdool Karim, L. Morris; CAPRISA002 Study Team, The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection. J. Virol. 85, 4828-4840 (2011).
29. R. M. Lynch, L. Tran, M. K. Louder, S. D. Schmidt, M. Cohen, C. H. A. V. I. 001 Clinical Team Members, R. Dersimonian, Z. Euler, E. S. Gray, S. Abdool Karim, J. Kirchherr, D. C. Montefiori, S. Sibeko, K. Soderberg, G. Tomaras, Z. Y. Yang, G. J. Nabel, H. Schuitemaker, L. Morris, B. F.Haynes, J. R. Mascola, The development of CD4 binding site antibodies during HIV-1 infection. J. Virol. 86, 7588-7595 (2012).
30. L. M. Walker, D. Sok, Y. Nishimura, O. Donau, R. Sadjadpour, R. Gautam, M. Shingai, R. Pejchal, A. Ramos, M. D. Simek, Y. Geng, I. A. Wilson, P. Poignard, M. A. Martin, D. R. Burton, Rapid development of glycan-specific, broad, and potent anti-HIV-1 gp120 neutralizing antibodies in an R5 SIV/HIV chimeric virus infected macaque. Proc. Natl. Acad. Sci. U.S.A. 108, 20125-20129 (2011).
31. M. Pancera, Y. Yang, M. K. Louder, J. Gorman, G. Lu, J. S. McLellan, J. Stuckey, J. Zhu, D. R. Burton, W. C. Koff, J. R. Mascola, P. D. Kwong, N332-directed broadly neutralizing antibodies use diverse modes of HIV-1 recognition: Inferences from heavy-light chain complementation of function. PLOS One 8, e55701 (2013).
32. M. Huber, K. M. Le, K. J. Doores, Z. Fulton, R. L. Stanfield, I. A. Wilson, D. R. Burton, Very few substitutions in a germ line antibody are required to initiate significant domain exchange. J. Virol. 84, 10700-10707 (2010).
33. P. L. Moore, E. S. Gray, C. K. Wibmer, J. N. Bhiman, M. Nonyane, D. J. Sheward, T. Hermanus, S. Bajimaya, N. L. Tumba, M. R. Abrahams, B. E. Lambson, N. Ranchobe, L. Ping, N. Ngandu, Q. A. Karim, S. S. A. Karim, R. I. Swanstrom, M. S. Seaman, C. Williamson, L. Morris, Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape. Nat. Med. 18, 1688-1692 (2012).
34. M. D. Simek, W. Rida, F. H. Priddy, P. Pung, E. Carrow, D. S. Laufer, J. K. Lehrman, M. Boaz, T. Tarragona-Fiol, G.Miiro, J. Birungi, A. Pozniak, D. A. McPhee, O. Manigart, E. Karita, A. Inwoley, W. Jaoko, J. Dehovitz, L. G. Bekker, P. Pitisuttithum, R. Paris, L. M. Walker, P. Poignard, T. Wrin, P. E. Fast, D. R. Burton, W. C. Koff, Human immunodeficiency virus type 1 elite neutralizers: Individuals with broad and potent neutralizing activity identified by using a highthroughput neutralization assay together with an analytical selection algorithm. J. Virol. 83, 7337-7348 (2009).
35. D. Sok, U. Laserson, J. Laserson, Y. Liu, F. Vigneault, J. P. Julien, B. Briney, A. Ramos, K. F. Saye, K. Le, A. Mahan, S. Wang, M. Kardar, G. Yaari, L. M. Walker, B. B. Simen, E. P. St John, P. Y. Chan-Hui, K. Swiderek, S. H. Kleinstein, G. Alter, M. S. Seaman, A. K. Chakraborty, D. Koller, I. A. Wilson, G. M. Church, D. R. Burton, P. Poignard, The effects of somatic hypermutation on neutralization and binding in the PGT121 family of broadly neutralizing HIV antibodies. PLOS Pathog. 9, e1003754 (2013).
36. L. M. Walker, M. D. Simek, F. Priddy, J. S. Gach, D. Wagner, M. B. Zwick, S. K. Phogat, P. Poignard, D. R. Burton, A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals. PLOS Pathog. 6, e1001028 (2010).
37. B. K. Choi, P. Bobrowicz, R. C. Davidson, S. R. Hamilton, D. H. Kung, H. Li, R. G. Miele, J. H. Nett, S. Wildt, T. U. Gerngross, Use of combinatorial genetic libraries to humanize N-linked glycosylation in the yeast Pichia pastoris. Proc. Natl. Acad. Sci. U.S.A. 100, 5022-5027 (2003).
38. V. T. Chang, M. Crispin, A. R. Aricescu, D. J. Harvey, J. E. Nettleship, J. A. Fennelly, C. Yu, K. S. Boles, E. J. Evans, D. I. Stuart, R. A. Dwek, E. Y. Jones, R. J. Owens, S. J. Davis, Glycoprotein structural genomics: Solving the glycosylation problem. Structure 15, 267-273 (2007).
39. J. S. McLellan, M. Pancera, C. Carrico, J. Gorman, J. P. Julien, R. Khayat, R. Louder, R. Pejchal, M. Sastry, K. Dai, S. O'Dell, N. Patel, S. Shahzad-ul-Hussan, Y. Yang, B. Zhang, T. Zhou, J. Zhu, J. C. Boyington, G. Y. Chuang, D. Diwanji, I. Georgiev, Y. D. Kwon, D. Lee, M. K. Louder, S. Moquin, S. D. Schmidt, Z. Y. Yang, M. Bonsignori, J. A. Crump, S. H. Kapiga, N. E. Sam, B. F. Haynes, D. R. Burton, W. C. Koff, L. M. Walker, S. Phogat, R. Wyatt, J. Orwenyo, L. X. Wang, J. Arthos, C. A. Bewley, J. R. Mascola, G. J. Nabel, W. R. Schief, A. B. Ward, I. A. Wilson, P. D. Kwong, Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 480, 336- 343 (2011).
40. C. N. Scanlan, J. Offer, N. Zitzmann, R. A. Dwek, Exploiting the defensive sugars of HIV-1 for drug and vaccine design. Nature 446, 1038-1045 (2007).
41. M. Pancera, S. Majeed, Y. E. A. Ban, L. Chen, C. C. Huang, L. Kong, Y. D. Kwon, J. Stuckey, T. Zhou, J. E. Robinson, W. R. Schief, J. Sodroski, R. Wyatt, P. D. Kwong, Structure of HIV-1 gp120 with gp41-interactive region reveals layered envelope architecture and basis of conformational mobility. Proc. Natl. Acad. Sci. U.S.A. 107, 1166-1171 (2010).
42. D. W. Kulp, S. Subramaniam, J. E. Donald, B. T. Hannigan, B. K. Mueller, G. Grigoryan, A. Senes, Structural informatics, modeling, and design with an open-source Molecular Software Library (MSL). J. Comput. Chem. 33, 1645-1661 (2012).
43. A. J. Petrescu, A. L. Milac, S. M. Petrescu, R. A. Dwek, M. R. Wormald, Statistical analysis of the protein environment of N-glycosylation sites: Implications for occupancy, structure, and folding. Glycobiology 14, 103-114 (2004).
44. M. R. Wormald, A. J. Petrescu, Y. L. Pao, A. Glithero, T. Elliott, R. A. Dwek, Conformational studies of oligosaccharides and glycopeptides: Complementarity of NMR, X-ray crystallography, and molecular modelling. Chem. Rev. 102, 371-386 (2002).